Thermo Fisher Scientific Inc. (0R0H.L)
USD 413.48
(-6.98%)
USD 413.48
(-6.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 51.88 Billion USD | -2.12% |
| 2022 | 53 Billion USD | -2.11% |
| 2021 | 54.14 Billion USD | 56.79% |
| 2020 | 34.53 Billion USD | 20.31% |
| 2019 | 28.7 Billion USD | 0.21% |
| 2018 | 28.64 Billion USD | -8.35% |
| 2017 | 31.25 Billion USD | 28.27% |
| 2016 | 24.36 Billion USD | 25.07% |
| 2015 | 19.48 Billion USD | -12.64% |
| 2014 | 22.3 Billion USD | 48.62% |
| 2013 | 15 Billion USD | 25.27% |
| 2012 | 11.97 Billion USD | 1.56% |
| 2011 | 11.79 Billion USD | 95.75% |
| 2010 | 6.02 Billion USD | -2.34% |
| 2009 | 6.16 Billion USD | 0.11% |
| 2008 | 6.16 Billion USD | -8.27% |
| 2007 | 6.71 Billion USD | -8.59% |
| 2006 | 7.35 Billion USD | 404.05% |
| 2005 | 1.45 Billion USD | 60.04% |
| 2004 | 911.17 Million USD | -9.44% |
| 2003 | 1 Billion USD | -37.65% |
| 2002 | 1.61 Billion USD | -15.51% |
| 2001 | 1.91 Billion USD | -17.11% |
| 2000 | 2.3 Billion USD | -17.57% |
| 1999 | 2.79 Billion USD | -16.3% |
| 1998 | 3.33 Billion USD | 11.88% |
| 1997 | 2.98 Billion USD | 13.67% |
| 1996 | 2.62 Billion USD | 34.27% |
| 1995 | 1.95 Billion USD | 14.92% |
| 1994 | 1.7 Billion USD | 28.64% |
| 1993 | 1.32 Billion USD | 20.76% |
| 1992 | 1.09 Billion USD | 85.54% |
| 1991 | 590.5 Million USD | 18.48% |
| 1990 | 498.4 Million USD | 37.91% |
| 1989 | 361.4 Million USD | 17.11% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 51.39 Billion USD | 0.59% |
| 2024 Q1 | 51.47 Billion USD | -0.79% |
| 2024 Q2 | 50.96 Billion USD | -0.99% |
| 2023 Q1 | 52.22 Billion USD | -1.47% |
| 2023 Q3 | 51.59 Billion USD | 2.8% |
| 2023 FY | 51.88 Billion USD | -2.12% |
| 2023 Q2 | 50.19 Billion USD | -3.9% |
| 2023 Q4 | 51.88 Billion USD | 0.56% |
| 2022 Q1 | 51.61 Billion USD | -4.67% |
| 2022 FY | 53 Billion USD | -2.11% |
| 2022 Q4 | 53 Billion USD | 13.24% |
| 2022 Q3 | 46.8 Billion USD | -2.7% |
| 2022 Q2 | 48.1 Billion USD | -6.8% |
| 2021 Q3 | 34.89 Billion USD | 13.12% |
| 2021 Q4 | 54.14 Billion USD | 55.19% |
| 2021 Q1 | 30.87 Billion USD | -10.6% |
| 2021 FY | 54.14 Billion USD | 56.79% |
| 2021 Q2 | 30.84 Billion USD | -0.09% |
| 2020 Q2 | 31.71 Billion USD | 5.27% |
| 2020 Q3 | 32.23 Billion USD | 1.64% |
| 2020 Q4 | 34.53 Billion USD | 7.13% |
| 2020 FY | 34.53 Billion USD | 20.31% |
| 2020 Q1 | 30.12 Billion USD | 4.96% |
| 2019 Q4 | 28.7 Billion USD | 4.87% |
| 2019 FY | 28.7 Billion USD | 0.21% |
| 2019 Q1 | 27.9 Billion USD | -2.59% |
| 2019 Q3 | 27.37 Billion USD | -6.38% |
| 2019 Q2 | 29.24 Billion USD | 4.8% |
| 2018 Q3 | 28.18 Billion USD | -2.66% |
| 2018 Q4 | 28.64 Billion USD | 1.62% |
| 2018 FY | 28.64 Billion USD | -8.35% |
| 2018 Q1 | 30.45 Billion USD | -2.56% |
| 2018 Q2 | 28.95 Billion USD | -4.92% |
| 2017 Q1 | 24.41 Billion USD | 0.21% |
| 2017 FY | 31.25 Billion USD | 28.27% |
| 2017 Q3 | 31.28 Billion USD | 29.69% |
| 2017 Q4 | 31.25 Billion USD | -0.09% |
| 2017 Q2 | 24.12 Billion USD | -1.21% |
| 2016 Q1 | 22.02 Billion USD | 13.06% |
| 2016 Q2 | 20.98 Billion USD | -4.72% |
| 2016 Q3 | 26.35 Billion USD | 25.55% |
| 2016 Q4 | 24.36 Billion USD | -7.53% |
| 2016 FY | 24.36 Billion USD | 25.07% |
| 2015 Q3 | 20.29 Billion USD | -3.78% |
| 2015 FY | 19.48 Billion USD | -12.64% |
| 2015 Q1 | 21.94 Billion USD | -1.62% |
| 2015 Q2 | 21.09 Billion USD | -3.86% |
| 2015 Q4 | 19.48 Billion USD | -4.0% |
| 2014 Q4 | 22.3 Billion USD | 0.56% |
| 2014 Q3 | 22.18 Billion USD | -6.23% |
| 2014 Q2 | 23.65 Billion USD | -7.97% |
| 2014 Q1 | 25.7 Billion USD | 71.27% |
| 2014 FY | 22.3 Billion USD | 48.62% |
| 2013 Q1 | 11.81 Billion USD | -1.41% |
| 2013 Q4 | 15 Billion USD | 26.8% |
| 2013 Q3 | 11.83 Billion USD | 0.07% |
| 2013 Q2 | 11.82 Billion USD | 0.13% |
| 2013 FY | 15 Billion USD | 25.27% |
| 2012 FY | 11.97 Billion USD | 1.56% |
| 2012 Q4 | 11.97 Billion USD | -2.5% |
| 2012 Q3 | 12.28 Billion USD | 9.06% |
| 2012 Q1 | 11.53 Billion USD | -2.22% |
| 2012 Q2 | 11.26 Billion USD | -2.31% |
| 2011 FY | 11.79 Billion USD | 95.75% |
| 2011 Q4 | 11.79 Billion USD | 0.0% |
| 2011 Q3 | 11.79 Billion USD | 40.29% |
| 2011 Q2 | 8.4 Billion USD | 2.84% |
| 2011 Q1 | 8.17 Billion USD | 36.53% |
| 2010 Q1 | 6.14 Billion USD | -0.8% |
| 2010 FY | 6.02 Billion USD | -2.34% |
| 2010 Q3 | 6.14 Billion USD | 3.45% |
| 2010 Q4 | 5.98 Billion USD | -2.48% |
| 2010 Q2 | 5.93 Billion USD | -3.4% |
| 2009 FY | 6.16 Billion USD | 0.11% |
| 2009 Q2 | 6.07 Billion USD | 0.64% |
| 2009 Q1 | 6.04 Billion USD | -1.99% |
| 2009 Q4 | 6.19 Billion USD | 2.91% |
| 2009 Q3 | 6.01 Billion USD | -0.99% |
| 2008 Q2 | 6.61 Billion USD | -1.51% |
| 2008 Q1 | 6.71 Billion USD | -0.1% |
| 2008 FY | 6.16 Billion USD | -8.27% |
| 2008 Q3 | 6.46 Billion USD | -2.23% |
| 2008 Q4 | 6.16 Billion USD | -4.65% |
| 2007 Q2 | 6.74 Billion USD | -2.87% |
| 2007 Q1 | 6.93 Billion USD | -5.59% |
| 2007 FY | 6.71 Billion USD | -8.59% |
| 2007 Q3 | 6.72 Billion USD | -0.16% |
| 2007 Q4 | 6.71 Billion USD | -0.15% |
| 2006 FY | 7.35 Billion USD | 404.05% |
| 2006 Q3 | 1.38 Billion USD | -3.89% |
| 2006 Q1 | 1.36 Billion USD | -6.28% |
| 2006 Q2 | 1.43 Billion USD | 5.31% |
| 2006 Q4 | 7.35 Billion USD | 431.41% |
| 2005 Q4 | 1.45 Billion USD | 5.32% |
| 2005 Q1 | 877.77 Million USD | -3.67% |
| 2005 FY | 1.45 Billion USD | 60.04% |
| 2005 Q2 | 1.44 Billion USD | 64.2% |
| 2005 Q3 | 1.38 Billion USD | -3.93% |
| 2004 Q2 | 1.04 Billion USD | 1.35% |
| 2004 Q1 | 1.02 Billion USD | 2.13% |
| 2004 Q3 | 938.15 Million USD | -9.93% |
| 2004 FY | 911.17 Million USD | -9.44% |
| 2004 Q4 | 911.17 Million USD | -2.88% |
| 2003 FY | 1 Billion USD | -37.65% |
| 2003 Q1 | 1.32 Billion USD | -17.67% |
| 2003 Q2 | 1.09 Billion USD | -17.75% |
| 2003 Q3 | 887.31 Million USD | -18.8% |
| 2003 Q4 | 1 Billion USD | 13.39% |
| 2002 Q1 | 1.87 Billion USD | -1.79% |
| 2002 Q2 | 1.78 Billion USD | -4.94% |
| 2002 Q4 | 1.61 Billion USD | -5.68% |
| 2002 Q3 | 1.71 Billion USD | -4.05% |
| 2002 FY | 1.61 Billion USD | -15.51% |
| 2001 FY | 1.91 Billion USD | -17.11% |
| 2001 Q4 | 1.91 Billion USD | -9.23% |
| 2001 Q3 | 2.1 Billion USD | -5.21% |
| 2001 Q2 | 2.21 Billion USD | -3.0% |
| 2001 Q1 | 2.28 Billion USD | -0.68% |
| 2000 Q4 | 2.3 Billion USD | -5.72% |
| 2000 Q1 | 2.79 Billion USD | -0.18% |
| 2000 Q2 | 2.63 Billion USD | -5.71% |
| 2000 Q3 | 2.44 Billion USD | -7.11% |
| 2000 FY | 2.3 Billion USD | -17.57% |
| 1999 Q2 | 3.36 Billion USD | -2.32% |
| 1999 Q4 | 2.79 Billion USD | -19.7% |
| 1999 Q3 | 3.48 Billion USD | 3.34% |
| 1999 Q1 | 3.44 Billion USD | 3.25% |
| 1999 FY | 2.79 Billion USD | -16.3% |
| 1998 Q2 | 3.14 Billion USD | -1.34% |
| 1998 Q3 | 3.18 Billion USD | 1.27% |
| 1998 Q1 | 3.18 Billion USD | 6.69% |
| 1998 FY | 3.33 Billion USD | 11.88% |
| 1998 Q4 | 3.33 Billion USD | 4.96% |
| 1997 Q2 | 2.89 Billion USD | 0.72% |
| 1997 Q3 | 3.1 Billion USD | 7.32% |
| 1997 Q4 | 2.98 Billion USD | -3.82% |
| 1997 FY | 2.98 Billion USD | 13.67% |
| 1997 Q1 | 2.87 Billion USD | 9.33% |
| 1996 Q3 | 2.57 Billion USD | -6.22% |
| 1996 Q4 | 2.62 Billion USD | 2.02% |
| 1996 FY | 2.62 Billion USD | 34.27% |
| 1996 Q1 | 2.7 Billion USD | 38.12% |
| 1996 Q2 | 2.74 Billion USD | 1.61% |
| 1995 Q3 | 1.86 Billion USD | 2.01% |
| 1995 Q1 | 1.71 Billion USD | 0.99% |
| 1995 Q2 | 1.82 Billion USD | 6.14% |
| 1995 Q4 | 1.95 Billion USD | 5.11% |
| 1995 FY | 1.95 Billion USD | 14.92% |
| 1994 FY | 1.7 Billion USD | 28.64% |
| 1994 Q3 | 1.68 Billion USD | -2.73% |
| 1994 Q4 | 1.7 Billion USD | 1.27% |
| 1994 Q2 | 1.72 Billion USD | 25.21% |
| 1994 Q1 | 1.37 Billion USD | 4.29% |
| 1993 Q2 | 1.1 Billion USD | -0.48% |
| 1993 Q1 | 1.1 Billion USD | 1.18% |
| 1993 Q4 | 1.32 Billion USD | 10.88% |
| 1993 FY | 1.32 Billion USD | 20.76% |
| 1993 Q3 | 1.19 Billion USD | 8.16% |
| 1992 Q1 | 701.8 Million USD | 18.85% |
| 1992 Q2 | 713.9 Million USD | 1.72% |
| 1992 Q4 | 1.09 Billion USD | 4.42% |
| 1992 FY | 1.09 Billion USD | 85.54% |
| 1992 Q3 | 1.04 Billion USD | 46.97% |
| 1991 Q1 | 540.5 Million USD | 8.45% |
| 1991 Q3 | 514.8 Million USD | -1.11% |
| 1991 Q4 | 590.5 Million USD | 14.7% |
| 1991 FY | 590.5 Million USD | 18.48% |
| 1991 Q2 | 520.6 Million USD | -3.68% |
| 1990 Q3 | 499.4 Million USD | 5.49% |
| 1990 FY | 498.4 Million USD | 37.91% |
| 1990 Q1 | 331.5 Million USD | -8.27% |
| 1990 Q2 | 473.4 Million USD | 42.81% |
| 1990 Q4 | 498.4 Million USD | -0.2% |
| 1989 FY | 361.4 Million USD | 17.11% |
| 1989 Q3 | 324.2 Million USD | 0.0% |
| 1989 Q4 | 361.4 Million USD | 11.47% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -8214.49% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -41045.449% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -8299.465% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -19498.466% |
| bluebird bio, Inc. | 424.62 Million USD | -12118.81% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -75357.758% |
| Imunon, Inc. | 8.53 Million USD | -608122.777% |
| Editas Medicine, Inc. | 150.05 Million USD | -34476.425% |
| IQVIA Holdings Inc. | 20.56 Billion USD | -152.244% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -1380.077% |
| Myriad Genetics, Inc. | 312.9 Million USD | -16481.655% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -4989.661% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -10543.723% |
| Verastem, Inc. | 71.18 Million USD | -72786.142% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 24.65% |
| Waters Corporation | 3.47 Billion USD | -1392.415% |
| Biogen Inc. | 12.04 Billion USD | -330.737% |
| Nektar Therapeutics | 267.04 Million USD | -19328.862% |
| Perrigo Company plc | 6.04 Billion USD | -758.836% |
| Dynavax Technologies Corporation | 375.02 Million USD | -13734.848% |
| Illumina, Inc. | 4.36 Billion USD | -1088.365% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -147393.619% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -26406.861% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -20129.337% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -139029.036% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -2645.107% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -62840.813% |
| Evolus, Inc. | 209.68 Million USD | -24643.546% |
| Adicet Bio, Inc. | 37.12 Million USD | -139673.707% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -128881.256% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | -630.031% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -7751.814% |
| FibroGen, Inc. | 585.72 Million USD | -8758.036% |
| Agilent Technologies, Inc. | 4.91 Billion USD | -954.982% |
| OPKO Health, Inc. | 622.47 Million USD | -8235.06% |
| Homology Medicines, Inc. | 118.53 Million USD | -43671.777% |
| Geron Corporation | 146.12 Million USD | -35406.101% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -1180.921% |
| Exelixis, Inc. | 678.44 Million USD | -7547.488% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -258402.317% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -413846.067% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -20586.74% |
| Zoetis Inc. | 9.29 Billion USD | -458.193% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -12960.497% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -105406.751% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | -907.495% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -106998.772% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -1892.943% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -2057.125% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -45090.398% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -3045.51% |
| Blueprint Medicines Corporation | 918.64 Million USD | -5547.908% |
| Insmed Incorporated | 1.66 Billion USD | -3022.232% |
| TG Therapeutics, Inc. | 169.08 Million USD | -30585.158% |
| Incyte Corporation | 1.59 Billion USD | -3158.493% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -4276.181% |